1. Home
  2. QNST vs ANL Comparison

QNST vs ANL Comparison

Compare QNST & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuinStreet Inc.

QNST

QuinStreet Inc.

HOLD

Current Price

$18.30

Market Cap

1.1B

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$15.02

Market Cap

998.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNST
ANL
Founded
1999
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
998.8M
IPO Year
2009
2022

Fundamental Metrics

Financial Performance
Metric
QNST
ANL
Price
$18.30
$15.02
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$24.75
$20.00
AVG Volume (30 Days)
812.2K
164.7K
Earning Date
05-07-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
1650.00
N/A
EPS
1.40
N/A
Revenue
$282,140,000.00
N/A
Revenue This Year
$18.59
$36.02
Revenue Next Year
$14.80
N/A
P/E Ratio
$13.13
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.29
$0.88
52 Week High
$22.29
$17.25

Technical Indicators

Market Signals
Indicator
QNST
ANL
Relative Strength Index (RSI) 48.38 66.54
Support Level $11.08 $12.07
Resistance Level $21.23 $17.25
Average True Range (ATR) 0.77 1.09
MACD -0.28 0.08
Stochastic Oscillator 31.02 93.36

Price Performance

Historical Comparison
QNST
ANL

About QNST QuinStreet Inc.

QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. The company operates as one reportable segment. The company generates majority of revenue from United States. The company's products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and Cloud Control Media.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: